title: FK-3000 isolated from Stephania delavayi Diels. inhibits MDA-MB-231 cell proliferation by decreasing NF-κB phosphorylation and COX-2 expression.
abstract: The World Health Organization (WHO) has reported that cancer is one of the most prevalent diseases and a leading cause of death worldwide. Many anticancer drug development studies have been pursued over the last few decades and several viable drugs have been discovered, such as paclitaxel, topotecan and irinotecan. Previously, our research group uncovered the cytocidal and cytostatic effects of the plant Stephania delavayi Diels. In this study, we determined the active chemical to be 6,7-di-O-acetylsinococuline (FK-3000). The FK-3000 half maximal inhibitory concentration (IC50) in MDA-MB-231 breast carcinoma cells at 48 h was 0.52 µg/ml and it induced apoptosis in a dose- and time-dependent manner. FK-3000 suppressed NF-κB nuclear translocation, decreased NF-κB phosphorylation, and decreased COX-2 protein expression. MDA-MB-231 xenografted mice were treated with FK-3000, Taxol, or their combination for 21 days. The tumor size was smallest in the co-treatment group, indicating that FK-3000 may have a synergistic effect with Taxol. FK-3000 treatment showed no adverse effects on blood cell counts, serum protein levels, or pathology. These studies demonstrate that FK-3000, isolated from S. delavayi Diels., is a promising, pathway-specific anticancer agent that exhibits low toxicity.
authors.affiliation: School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450001, P.R. China.
authors.forename: Hong De
authors.initials: HD
authors.lastname: Xu
authors.affiliation: NaturePureKorea Inc., Jeonnam 517-8-3, Republic of Korea.
authors.forename: Soon-Chang
authors.initials: SC
authors.lastname: Cho
authors.affiliation: Research Development Team, Jeonnam Biofood Technology Center, Jeonnam, Naju 520-330, Republic of Korea.
authors.forename: Mi-Ae
authors.initials: MA
authors.lastname: Bang
authors.affiliation: College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Republic of Korea.
authors.forename: Chun-Sik
authors.initials: CS
authors.lastname: Bae
authors.affiliation: Department of Bio Medical Analysis, Korea Polytechnic College, Nonsan, Chungnam 320-905, Republic of Korea.
authors.forename: Yeonshik
authors.initials: Y
authors.lastname: Choi
authors.affiliation: NaturePureKorea Inc., Jeonnam 517-8-3, Republic of Korea.
authors.forename: Yong-Chun
authors.initials: YC
authors.lastname: Li
authors.affiliation: Department of Exercise Prescription, Dongshin University, Naju, Jeonnam 520-714, Republic of Korea.
authors.forename: Seung-Kil
authors.initials: SK
authors.lastname: Lim
authors.affiliation: Comparative Biomedicine Research Branch, National Cancer Center, Goyang-si, Gyeonggi-do 411-769, Republic of Korea.
authors.forename: Jaegal
authors.initials: J
authors.lastname: Shim
authors.affiliation: Department of Oriental Medicine Materials, Dongshin University, Naju, Jeonnam 520-714, Republic of Korea.
authors.forename: Dae-Hun
authors.initials: DH
authors.lastname: Park
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019073:HT29 Cells; D006801:Humans; D061986:MCF-7 Cells; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D010766:Phosphorylation; D023041:Xenograft Model Antitumor Assays
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; C442856:FK3000; D016328:NF-kappa B; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D017239:Paclitaxel
references.citation: Biol Pharm Bull. 1999 Mar;22(3):268-74
references.pmid: 10220283
references.citation: Science. 1998 Sep 11;281(5383):1680-3
references.pmid: 9733516
references.citation: Cancer Res. 1999 Jul 15;59(14):3299-303
references.pmid: 10416581
references.citation: Cancer Res. 2004 Dec 15;64(24):9086-92
references.pmid: 15604277
references.citation: Biochem Pharmacol. 2006 May 14;71(10):1397-421
references.pmid: 16563357
references.citation: Clin Cancer Res. 2007 May 1;13(9):2784-94
references.pmid: 17473212
references.citation: Cancer Lett. 2007 Jun 28;251(2):237-46
references.pmid: 17189670
references.citation: Mol Cell Biochem. 2007 Aug;302(1-2):187-94
references.pmid: 17387583
references.citation: Histol Histopathol. 2007 Dec;22(12):1387-98
references.pmid: 17701919
references.citation: Am J Prev Med. 2007 Dec;33(6 Suppl):S318-26
references.pmid: 18021906
references.citation: Neoplasia. 2007 Nov;9(11):893-9
references.pmid: 18030357
references.citation: Pharmacol Rep. 2008 Jan-Feb;60(1):93-100
references.pmid: 18276990
references.citation: Cell Biol Int. 2008 May;32(5):494-501
references.pmid: 18078766
references.citation: Bioorg Med Chem. 2008 Jun 1;16(11):6186-92
references.pmid: 18456502
references.citation: Int J Oncol. 2008 Oct;33(4):807-14
references.pmid: 18813795
references.citation: Mol Cancer Ther. 2010 Nov;9(11):2914-23
references.pmid: 20978163
references.citation: Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
references.pmid: 20493977
references.citation: Oncol Rep. 2011 Oct;26(4):833-41
references.pmid: 21725607
references.citation: Ann N Y Acad Sci. 2011 Jul;1229:18-22
references.pmid: 21793834
references.citation: Br J Cancer. 2012 Aug 7;107(4):652-7
references.pmid: 22805327
references.citation: Molecules. 2014;19(8):11679-721
references.pmid: 25102117
references.citation: Cancer Lett. 2005 Jun 16;224(1):53-65
references.pmid: 15911101
references.citation: J Clin Invest. 2005 Oct;115(10):2625-32
references.pmid: 16200195
references.citation: J Biol Chem. 2000 Dec 15;275(50):39507-15
references.pmid: 10993880
references.citation: Nature. 2000 Apr 20;404(6780):892-7
references.pmid: 10786798
references.citation: J Cell Biochem. 2006 May 1;98(1):221-33
references.pmid: 16408291
references.citation: Phytother Res. 2001 Sep;15(6):497-500
references.pmid: 11536378
references.citation: J Biol Chem. 2001 Dec 28;276(52):48921-9
references.pmid: 11679590
references.citation: J Natl Cancer Inst. 2002 Feb 20;94(4):252-66
references.pmid: 11854387
references.citation: Lancet Oncol. 2001 Sep;2(9):544-51
references.pmid: 11905709
references.citation: Phytother Res. 2002 Mar;16(2):186-9
references.pmid: 11933126
references.citation: Chem Pharm Bull (Tokyo). 2002 Jun;50(6):877-80
references.pmid: 12045355
references.citation: Trends Mol Med. 2002 Aug;8(8):385-9
references.pmid: 12127724
references.citation: N Engl J Med. 2002 Dec 26;347(26):2104-10
references.pmid: 12501222
references.citation: Pharmacol Ther. 2003 Jul;99(1):1-13
references.pmid: 12804695
references.citation: Hepatology. 2003 Sep;38(3):756-68
references.pmid: 12939602
references.citation: J Natl Cancer Inst. 2003 Nov 5;95(21):1578-86
references.pmid: 14600090
references.citation: Nat Rev Drug Discov. 2004 Jan;3(1):17-26
references.pmid: 14708018
references.citation: Mol Cells. 2004 Feb 29;17(1):45-50
references.pmid: 15055526
references.citation: Curr Top Med Chem. 2004;4(9):871-82
references.pmid: 15134546
references.citation: Mol Cancer. 2004 Mar 11;3:7
references.pmid: 15016316
references.citation: Chem Pharm Bull (Tokyo). 1987 Apr;35(4):1660-2
references.pmid: 3652302
references.citation: Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12740-4
references.pmid: 7809113
references.citation: Cancer Lett. 1996 Feb 6;99(2):217-24
references.pmid: 8616827
references.citation: Exp Cell Res. 1997 Nov 25;237(1):101-9
references.pmid: 9417872
references.citation: Mol Cell Biol. 1999 Aug;19(8):5785-99
references.pmid: 10409765